Fourth-generation allosteric EGFR inhibitors: Structure-based scaffold analysis and SAR exploration
Bioorganic Chemistry · 2026-10 · 181 · 110299
DOI: 10.1016/j.bioorg.2026.110299 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2026-10. Verfasst von Ibrahim Mohammed Hepishy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Galala University, New Galala, 43713, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
The development of the C797S resistance mutation to third-generation tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer is a key therapeutic barrier, and this renders standard orthosteric site competitive inhibitors futile. Allosteric inhibitors of EGFR have emerged as a promising strategy for overcoming this resistance mechanism due to a structurally distinct binding site approximately 15-20 Å from the C797S mutation that confers potency independent of the status of cysteine-797. This comprehensive review summarizes the last decade of allosteric EGFR inhibitor medicinal chemistry, including 185 compounds across eight scaffold classes representing the entire reported landscape of efforts toward targeting EGFR with small molecules allosterically. The aminothiazole scaffold dominates the field with 57 compounds, followed by 4-anilinoquinazoline with 39 compounds; the focus of the field is concentrated on these privileged scaffolds. Five universal design principles governing allosteric potency have been identified through structure-activity relationship analysis: the formation of a hydrogen bond network, complementarity to a hydrophobic pocket, bivalent binding architecture based on a dual heterocycle, precise linker geometry, and core heterocycle identity. These principles account for the spectacular potency achievements that include 11 compounds reaching ultra-nanomolar potency (IC₅₀ < 1 nM) and 54 compounds attaining single-digit nanomolar activity. The aminothiazole-isoindolinone hybrid attained the most potent compound 4 with 0.10 nM, which is 20-fold, improved from the foundational EAI045 compound. The maturity of the field peaked in 2022 in optimization efforts, with 85 compounds reported. This review establishes that allosteric EGFR inhibition represents a clinically viable strategy for addressing osimertinib resistance, with lead candidates ready for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Faculty of Pharmacy, Galala University, New Galala, 43713, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sinai University-Arish branch, Arish, Egypt.
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City 11884, Cairo, Egypt; Pharmaceutical Chemistry Department, College of Pharmacy, The Islamic University, Najaf, Iraq.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt; Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Az…
- Pharmaceutical Organic Chemistry Department Faculty of Pharmacy, Capital University (Formerly Helwan University, Ain Helwan Cairo 11795, Egypt.
Zitieren
APA
Hepishy, I. M., Salem, M., El-Morsy, A., El-Adl, K., & Ahmed, N. M. (2026). Fourth-generation allosteric EGFR inhibitors: Structure-based scaffold analysis and SAR exploration. Bioorganic Chemistry, 181, 110299. https://doi.org/10.1016/j.bioorg.2026.110299
Vancouver
Hepishy IM, Salem M, El-Morsy A, El-Adl K, Ahmed NM. Fourth-generation allosteric EGFR inhibitors: Structure-based scaffold analysis and SAR exploration. Bioorganic Chemistry. 2026;181:110299. doi:10.1016/j.bioorg.2026.110299
BibTeX
@article{Hepishy2026,
author = {Hepishy, Ibrahim Mohammed and Salem, Mo'men and El-Morsy, Ahmed and El-Adl, Khaled and Ahmed, Naglaa M},
title = {Fourth-generation allosteric EGFR inhibitors: Structure-based scaffold analysis and SAR exploration},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {181},
pages = {110299},
doi = {10.1016/j.bioorg.2026.110299}
}
EUVIMED